Literature DB >> 1958520

Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones.

A L Schuurmans1, J Bolt, J Veldscholte, E Mulder.   

Abstract

The mitogenic activity of several growth factors on androgen responsive LNCaP human prostate tumor cells was studied. A two-fold stimulation of cell proliferation was observed after a culture period of 6 days in 1 ng EGF/ml, 10 ng TGF-alpha/ml or 20 ng basic FGF/ml. TGF-beta (0.02 ng/ml), which did not affect cell proliferation when added alone to the culture medium, inhibited the EGF- and TGF-alpha-induced growth. The synthetic androgen R1881 (0.1 nM) stimulated cell proliferation three-fold and increased the number of EGF receptors from 11500 to 28500 sites/cell. One of the mechanisms involved in androgen action on these cells is therefore an increased EGF receptor expression and increased sensitivity to EGF. TGF-beta did not directly affect androgen-responsive growth but inhibited the synergistic effect of EGF. A considerable expression of TGF alpha (precursors) could be demonstrated on the cells by immunohistochemical staining. However the staining intensity was not affected by androgens. These results make it less likely that androgen-responsive growth is mediated by regulation of secretion of an EGF- or TGF alpha-like activity, which in turn acts in an autocrine manner to stimulate growth. Estrogens, progestagens and antiandrogens do not inhibit androgen responsive growth of LNCaP cells but have striking growth stimulatory effects, increase EGF receptor level and increase acid phosphatase secretion. LNCaP cells contain a modified androgen receptor system with respect to both steroid specificity and antiandrogen sensitivity. It has recently been shown that the stimulatory effects are due to a mutated amino acid in the steroid binding domain of the androgen receptor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1958520     DOI: 10.1016/0960-0760(91)90182-5

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  12 in total

1.  Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation.

Authors:  A Migliaccio; G Castoria; M Di Domenico; A de Falco; A Bilancio; M Lombardi; M V Barone; D Ametrano; M S Zannini; C Abbondanza; F Auricchio
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

2.  Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.

Authors:  J Mad'arová; M Lukesová; A Hlobilková; M Strnad; B Vojtesek; R Lenobel; M Hajdúch; P G Murray; S Perera; Z Kolár
Journal:  Mol Pathol       Date:  2002-08

3.  Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.

Authors:  Jerome C Nwachukwu; Paolo Mita; Rachel Ruoff; Susan Ha; Qianben Wang; S Joseph Huang; Samir S Taneja; Myles Brown; William L Gerald; Michael J Garabedian; Susan K Logan
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

Review 4.  The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance.

Authors:  Jelani C Zarif; Cindy K Miranti
Journal:  Cell Signal       Date:  2016-01-29       Impact factor: 4.315

5.  Using in vitro high throughput screening assays to identify potential endocrine-disrupting chemicals.

Authors:  Daniel M Rotroff; David J Dix; Keith A Houck; Thomas B Knudsen; Matthew T Martin; Keith W McLaurin; David M Reif; Kevin M Crofton; Amar V Singh; Menghang Xia; Ruili Huang; Richard S Judson
Journal:  Environ Health Perspect       Date:  2012-09-28       Impact factor: 9.031

6.  Retinoids regulate the formation and degradation of gap junctions in androgen-responsive human prostate cancer cells.

Authors:  Linda Kelsey; Parul Katoch; Kristen E Johnson; Surinder K Batra; Parmender P Mehta
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

7.  Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells.

Authors:  D Seth; K Shaw; J Jazayeri; P J Leedman
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

8.  Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.

Authors:  D N Grigoryev; B J Long; I P Nnane; V C Njar; Y Liu; A M Brodie
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

9.  Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells.

Authors:  M E Harper; E Glynne-Jones; L Goddard; V J Thurston; K Griffiths
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

10.  Induction of transforming growth factor beta in hormonally treated human prostate cancer.

Authors:  G H Muir; A Butta; R J Shearer; C Fisher; D P Dearnaley; K C Flanders; M B Sporn; A A Colletta
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.